Vinta Bio, Inc.
Welcome to Vinta Bio, production excellence in viral vectors
Vinta Bio, Inc. provides CDMO (Contract Development and Manufacturing Organization) services in producing GMP-grade and research-grade viral vectors, such as but not limited to adeno-associated (AAV) and lenti viral vectors, as the carrying agents for a number of disease targets for its customers such as biotech and pharmaceutical companies, and academic research institutes and laboratories. The founders and management are at the top of the industry, who are the only ones having manufactured the early AAV vectors of the only two FDA-approved AAV gene therapy products, Luxturna and Zolgensma, and played critical roles in CMC filing for Luxturna.
Vinta Bio has built a highly efficient and highly productive master cell bank, and just moved into a new state-of-the-art 22,000 sqf GMP manufacturing facility in Navy Yard in Philadelphia. The facility has 2 independent production rooms, 2 additional reserved production rooms, and a dedicated fill-and-finish room. It has on-site process development and analytical capabilities. Future expansion is planned in 2023, with additional cell therapy manufacturing as well as Phase III and commercial production.
Brands: Vinta Bio, Inc. provides CDMO services, from Philadelphia, in producing GMP-grade and research-grade viral vectors, such as adeno-associated (AAV) and lenti viral vectors, for its customers.